Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579602 · ClinicalTrials.gov registry record · Phase 2
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
A Phase 2 study, sponsored by Blaze Bioscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT03579602 is a Phase 2 study that has completed, run by Blaze Bioscience. The registered enrollment target is 118 participants.
The verdict
NCT03579602, a Phase 2 study, has completed, sponsored by Blaze Bioscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. Tozuleristide is a drug that is thought to attach to tumor tissue and then fluoresces (glows) when a special light from the Canvas is shined on it. It is hypothesized that tozuleristide, when imaged with the Canvas, will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor or other ambiguous tissue in real-time as they operate. The purpose of this study is to evaluate how well tozuleristide imaged with Canvas work at helping to distinguish between tumor and normal tissue during surgery in pediatric primary central nervous system tumors.
Interventions
- DRUG tozuleristide
- DEVICE Canvas System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2018-11-26 |
| Est. Completion | 2022-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579602
The ClinicalTrials.gov registry entry for NCT03579602 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blaze Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tozuleristide is the first listed.
NCT03579602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579602 about?
NCT03579602 is a clinical study titled "Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery". Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor...
What is the current status of trial NCT03579602?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2018-11-26. Estimated completion is 2022-06-13.
What interventions are being tested in trial NCT03579602?
The interventions under investigation include: tozuleristide (DRUG), Canvas System (DEVICE).
Who is sponsoring clinical trial NCT03579602?
This trial is sponsored by Blaze Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.